Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplasm Metastasis 1Leiomyosarcoma 1Gastrointestinal Stromal Tumors 1

Interventions

Imatinib Mesylate 19Sunitinib 9nilotinib 4ripretinib 3regorafenib 2masitinib 2tanespimycin 1famitinib 1avapritinib 1Sodium Chloride 1Midazolam 1Mastectomy, Segmental 1Immunoglobulin G 1IDRX-42 1Fentanyl 1Disulfides 1Carnitine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gastrointestinal Stromal Tumors × Midazolam × Clear all
NCT05208047 2026-05-22

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Cogent Biosciences, Inc.

Phase 3 Active not recruiting
482 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡